



## Europass Curriculum Vitae

### Personal information

Surname(s) / First name(s) **Fumagalli, Elena Rosa**

Address(es) Istituto Nazionale Tumori, via G. Venezian 1, 20133, Milano, Italy

Telephone(s) +39 02 2390 2182

Fax(es) +39 02 2390 2804

E-mail elenarosa.fumagalli@istitutotumori.mi.it

Nationality Italian

Date of birth 29 September 1970

Gender Female

### Work experience

Dates	From May 2017 to now
Occupation or position held	Consultant – Adult Mesenchymal Tumour & Rare cancer Medical Oncology Unit
Main activities and responsibilities	Medical Oncologist
Name and address of employer	Fondaz. IRCCS “Istituto Nazionale dei Tumori”, via G. Venezian 1, 20133 Milano, Italy
Name and address of employer	Medical oncology involved in adult patients with sarcoma and other rare solid tumor care
Dates	From December 2014 to April 2017
Occupation or position held	Free lance Physician – Adult Mesenchymal Tumour & Rare cancer Medical Oncology Unit
Main activities and responsibilities	Medical Oncologist
Name and address of employer	Fondaz. IRCCS “Istituto Nazionale dei Tumori”, via G. Venezian 1, 20133 Milano, Italy
Name and address of employer	Medical oncology involved in adult patients with sarcoma and other rare solid tumor care
Dates	From September 2011 to December 2014
Occupation or position held	Free lance Physician – Adult Mesenchymal Tumour Medical Oncology Unit
Main activities and responsibilities	Medical Oncologist
Name and address of employer	Fondaz. IRCCS “Istituto Nazionale dei Tumori”, via G. Venezian 1, 20133 Milano, Italy

Name and address of employer	Medical oncology involved in adult patients with sarcoma and other rare solid tumor care
Dates	From March 2011 to September 2011
Occupation or position held	Permanent full staff position – Adult Mesenchymal Tumour Medical Oncology Unit
Main activities and responsibilities	Medical Oncologist
Name and address of employer	Fondaz. IRCCS "Istituto Nazionale dei Tumori", via G. Venezian 1, 20133 Milano, Italy
Type of business	Medical oncology involved in adult patients with sarcoma and other rare solid tumor care
Dates	From May 2002 to January 2011
Occupation or position held	Free lance Physician – Adult Mesenchymal Tumour Medical Oncology Unit
Main activities and responsibilities	Medical Oncologist
Name and address of employer	Fondaz. IRCCS "Istituto Nazionale dei Tumori", via G. Venezian 1, 20133 Milano, Italy
Type of business	Medical oncology involved in adult patients with sarcoma and other rare solid tumor care
Dates	From November 2001 to April 2002
Occupation or position held	Clinical Fellow
Main activities and responsibilities	Physician
Name and address of employer	Azienda ospedaliera S. Gerardo dei Tintori, Monza
Type of business	Medical oncology
Dates	From May 2000 to October 2001
Occupation or position held	Board certificate in Medical Oncology
Main activities and responsibilities	Physician
Name and address of employer	Azienda ospedaliera S. Gerardo dei Tintori, Monza
Type of business or sector	Medical oncology
Dates	From January 2000 to April 2000
Occupation or position held	Permanent full staff position
Main activities and responsibilities	Physician
Name and address of employer	Azienda ospedaliera S. Gerardo dei Tintori, Monza
Type of business or sector	Medical oncology
Dates	From 1999 to January 2000
Occupation or position held	Board certificate in Medical Oncology
Main activities and responsibilities	Physician
Name and address of employer	Azienda ospedaliera S. Gerardo dei Tintori, Monza
Type of business	Medical oncology
Dates	From 1997 to January 1999
Occupation or position held	Board certificate in Medical Oncology
Main activities and responsibilities	Physician
Name and address of employer	Azienda ospedaliera S. Gerardo dei Tintori, Monza

Type of business Medical Oncology

## Education and training

Dates 2001

Title of qualification awarded **Oncologist**

Principal subjects/occupational skills covered Medical Oncology

Name and type of organisation providing education and training Università degli studi , Milan

Dates 1997

Title of qualification awarded **Italian Medical Licence**

Principal subjects/occupational skills covered Medicine

Name and type of organisation providing education and training Università degli studi , Milan

Dates From 1992 to 1997

Title of qualification awarded **Medical Degree** (cum laude)

Principal subjects/occupational skills covered Medicine

Name and type of organisation providing education and training Università degli studi , Milan

Level in national or international classification ISCED 5A (Field of Education: 72)

## Personal skills and competences

Mother tongue(s) **Italian**

Other language(s) **English**

Self-assessment

European level (\*)

**English**

Understanding				Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production			
C1	Basic	C1	Basic	C1	Basic	C1	Basic	C1	Basic

(\*) Common European Framework of Reference for Languages

## Additional information

- Investigator Site personnel ICH GCP Training Certificate , 16 Feb 2021

## Annexes

Annex 1: List of Medline-indexed scientific publications, in English

## Annex 1

### List of Medline-indexed scientific publications, in English

- P. Lissoni, **E. Fumagalli**, F. Malugani, A. Ardizzoia, S. Secondino, G. Tancini, G. Gardani. *Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer.* Int J Biol Markers, 2000; 15: 308-311
- P. Lissoni, F. Brivio, R. Ferrante, L. Vigore, M. Vaghi, **E. Fumagalli**, R. Bocovec, F. Malugani, L. Fumagalli. *Circulating immature and mature dendritic cells in relation to lymphocyte subsets in patients with gastrointestinal tract cancer.* Int J Biol Markers, 2000;15: 22-25.
- P. Lissoni, M. Vaghi, A. Ardizzoia, **E. Fumagalli**, F. Malugani, G. Tancini, G. Gardani, Ario Conti, G. JM Maestroni. *Efficacy of monotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer.* Neuroendocrinology Letters 2001.; 22:27-29
- P. Lissoni, R. Rovelli, D. Vellani, F. Maligni, R. Bocovec, L. Chapovalenko, **E. Fumagalli**, G. Cardani. *Stimulation of IL-18 secretion by IL-2 in patients with advanced cancer.* Int J Biol Markers 2001; 16:146-147.
- P. Lissoni, **E. Fumagalli**, F. Malugani, A. Ardizzoia, R. Bucovec, G. Tancini, G. Gardani. *Stimulation of IL-12 secretion by GM-CSF in advanced cancer patients.* J Biol Regul Homost Agents 2001; 15:163-165
- P. Lissoni, M. Vaghi, A. Ardizzoia, F. Malugani, **E. Fumagalli**, V. Bordin, L. Fumagalli, A. Bordoni, S. Mengo, G. Gardani, G. Tancini. *A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.* In Vibo. 2002; 16:93-6.
- P. Lissoni, V. Bordin, M. Vaghi, L. Fumagalli, A. Bordoni, S. Mengo, R. Bocovec, **E. Fumagalli**, F. Malugani, A. Ardizzoia, L. Giani, G. Gardani, G. Tancini. *Ten-years survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.* Anticancer Res. 2002;22:1061-4
- P. Lissoni, F. Malugani, M. Casu, R. Bucovec, R. Egardi, V. Bordin, **E. Fumagalli**, S. Mengo, G. Cardani. *Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients.* Neuroendocrinology Letters 2002; 23:61-3
- P. G. Casali, A. Messina, S. Stacchiotti, E. Tamburini, F. Crippa, A. Gronchi, R. Orlandi, C. Ripamonti, C. Spreafico, R. Bertieri, R. Bertulli, M. Colecchia, **E. Fumagalli**, A. Greco, F. Grosso, P. Olmi, M. Pienotti, S. Pilotti. *Imatinib Mesylate in Chordoma.* Cancer 2004;101:2086-97.
- P. Casali, R. Bertulli, **E. Fumagalli**, P. Coco, F. Grosso, S. Stacchiotti. *Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors.* J Chemother. 2004; 16:55-58
- L. D. Locati, M. Guzzo, P. Bossi, P.P. Brega Massone, B. Conti, **E. Fumagalli**, C. Bareggi, G. Cantù, L. Licita. *Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland.* Oral Oncology 2005; 41: 890-94.
- G:D. Demetri, A.T. van Oosteron, C R Garrett, M. E. Blackstein, M.H. Shah, J. Verweij, G. McArthur, I.R. Judson, M. C. Heinrich, J.A. Morgan, J. Desai, C.D. Fletcher, S. George, C.L. Bello, X. Huang, C.M. Baum, P.G. Casali, **E. Fumagalli** (come partecipante allo Studio multicentrico multinazionale). *Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.* Lancet. 2006; 368:1329-38
- F. Miselli, T. Negri, A. Gronchi, M. Losa, E. Conca, S. Brich, **E. Fumagalli**, M. Fiore, P.G. Casali, M.A. Pierotti, E. Tamborini, S. Pilotti. *Is Autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors?* Translational Oncology 2008; vol 1 (4): 177-186
- M. Fiore, E. Palassini, **E. Fumagalli**, S. Pilotti, E. Tamborini, S. Stacchiotti, E. Pennachioli, P.G. Casali, A. Gronchi. *Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).* European Journal of Surgical Oncology 2009, doi:10.1016/j.ejso.2008.11.005
- T. Negri, F. Bozzi, E. Conca, S. Brich, A. Gronchi, R. Bertulli, **E. Fumagalli**, MA Pierotti, E Tamborini, S. Pilotti. *Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical sample of imatinib-treated gastrointestinal stromal tumours (GISTs).* Journal of Pathology 2009; 217: 103-112
- S. George, JY Blay, PG Casali, A Le Cesne, P Stephenson, SE Deprimo, CS Harmon, CN Law, JA Morgan, I Ray-Coquard, V Tassell, DP Cohen, GD Demetri. **E. Fumagalli** (come partecipante allo studio clinico internazionale) *Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.* Eur J Cancer 2009 45: 1959-68.

- E. Conca, T. Negri, A. Gronchi, **E. Fumagalli**, E. Tamborini, GM Pavan, M. Fermaglia, MA Pierotti, S. Pricl, S. Pilotti. *Activate and resist: L576P-KIT in GIST*. Mol Cancer Ther 2009; 8(9): 2491-95
- GD Demetri, PG Casali, JY Blay, M von Mehren, JA Morgan, R. Bertulli, I Ray-Coquard, P. Cassier, M Davey, H. Borghaei, D Pink, M Debiec-Rychter, W Cheung, SM Bailey, ML Veronese, A Reichardt, **E Fumagalli**, P. Reichardt. *A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors*. Clin Cancer Res. 2009 15;15(18):5910-6.
- MA Pierotti, E. Tamborini, T. Negri, S. Pricl, S. Pilotti. *Targeted therapy in giST: in silico modelling for prediction of resistance* Nat Rev Clin Oncol. 2011 Mar;8(3):161-70. Review. **E Fumagalli** (acknowledgments)
- P. Dileo, S. Pricl, E Tamborini, T. Negri, S. Stacchiotti, A. Gronchi, P. Posocco, E. Laurini, P. Coco, **E Fumagalli**, PG Casali, S. Pilotti *Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: an imaging, biochemical and molecular modeling study* Int J Cancer. 2011 Feb 15;128(4):983-90
- L. Da Riva, F. Bozzi, P. Mondellini, F. Miccichè, **E Fumagalli**, E. Vaghi, E. Tarantino, V. Huber, A. Gronchi, E. Tamborini, MA Pierotti, S. Pilotti, I. Bongarzone. *Proteomic detection of a large amount of SCGFa in the stroma of GISTs after imatinib therapy* J of Transl Med 2011 Sep 23;9:158
- PA Cassier, **E. Fumagalli**, P. Rutkowski, P. Schöffski, M. Van Glabbeke, M. Debiec-Rychter, JF Emile, F. Duffaud, J. Martin-Broto, B. Landi, A. Adenis, F. Bertucci, E. Bompas, O. Bouché, S. Leyvraz, I. Judson, J. Verweij, P. Casali, JY Blay, P. Hohenberger; European Organisation for Research and Treatment of Cancer. *Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era*. Clin Cancer Res. 2012 Aug 15;18(16):4458-64.
- PG Casali, **E Fumagalli**, A. Gronchi. *Adjuvant Therapy of Gastrointestinal Stromal Tumors (GIST)*. Curr Treat Options Oncol. 2012 Sep;13(3):277-84.
- S. Angelini, MA Pantaleo, G. Ravegnini, C. Zenesini, G. Cavrini, M. Nannini, **E Fumagalli**, E. Palassini, M. Saponara, M. Di Battista, PG Casali, P. Hrelia, G. Cantelli-Forti, G. Biasco. *Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy*. Pharmacol Res. 2012 Nov 2;68(1):1-6.
- E. Conca, C. Miranda, VD Col, **E Fumagalli**, G. Pelosi, M. Mazzoni, M. Fermaglia, E. Laurini, MA Pierotti, S. Pilotti, A. Greco, S. Pricl, E. Tamborini *Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib*. Mol Oncol. 2013 Aug;7(4):756-62
- Rutkowski P, Gronchi A, Hohenberger P, Bonvalot S, Schöffski P, Bauer S, **Fumagalli E**, Nyckowski P, Nguyen BP, Kerst JM, Fiore M, Bylina E, Hoiczky M, Cats A, Casali PG, Le Cesne A, Treckmann J, Stoeckle E, de Wilt JH, Sleijfer S, Tielen R, van der Graaf W, Verhoef C, van Coevorden F. *Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience*. Ann Surg Oncol. 2013 Sep;20(9):2937-43.
- Bauer S, Rutkowski P, Hohenberger P, Miceli R, **Fumagalli E**, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, Hoiczky M, Cats A, Casali PG, Treckmann J, van Coevorden F, Gronchi A. *Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study)*. Eur J Surg Oncol. 2014 Apr;40(4):412-9.
- Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, **Fumagalli E**, Provenzano S, Gronchi A, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, Casali PG, Zaffaroni N. *Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour*. Eur J Cancer. 2014 Nov;50(17):3021-8.
- Sanfilippo R, Bertulli R, Marrari A, **Fumagalli E**, Pilotti S, Morosi C, Messina A, Dei Tos AP, Gronchi A, Casali PG. *High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma*. Clin Sarcoma Res. 2014 Nov 22;4(1):16.
- Reichardt P, Kang YK, Rutkowski P, Schuette J, Rosen LS, Seddon B, Yalcin S, Gelderblom H, Williams CC Jr, **Fumagalli E**, Biasco G, Hurwitz HI, Kaiser PE, Fly K, Matczak E, Chen L, Lechuga MJ, Demetri GD. *Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib*. Cancer. 2015 May 1;121(9):1405-13.
- Angelini S, Ravegnini G, Nannini M, Bermejo JL, Musti M, Pantaleo MA, **Fumagalli E**, Venturoli N, Palassini E, Consolini N, Casali PG, Biasco G, Hrelia P. *Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome*. Eur J Hum Genet. 2015 Jun;23(6):817-23.
- Boikos SA, Xekouki P, **Fumagalli E**, Faucez FR, Raygada M, Szarek E, Ball E, Kim SY, Miettinen M, Helman LJ, Carney JA, Pacak K, Stratakis CA. *Carney triad can be (rarely) associated with germline succinate dehydrogenase defects*. Eur J Hum Genet. 2015 Jul 15.

- Vincenzi B, Nannini M, **Fumagalli E**, Bronte G, Frezza AM, De Lisi D, Spalato Ceruso M, Santini D, Badalamenti G, Pantaleo MA, Russo A, Dei Tos AP, Casali P, Tonini G. Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. *Oncotarget*. 2015 Sep 24.
- Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, **Fumagalli E**, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marréaud S, van der Graaf WT, Zalcborg JR, Litière S, Blay J Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. *J Clin Oncol*. 2015 Nov 16. pii: JCO.2015.62.4304.
- Boikos SA, Xekouki P, **Fumagalli E**, Faucez FR, Raygada M, Szarek E, Ball E, Kim SY, Miettinen M, Helman LJ, Carney JA, Pacak K, Stratakis CA. Carney triad can be (rarely) associated with germline succinate dehydrogenase defects. *Eur J Hum Genet*. 2016 Apr;24(4):569-73
- Khosravan R, Motzer RJ, **Fumagalli E**, Rini BI Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor. *Clin Pharmacokinet*. 2016 Oct;55(10):1251-69.
- MA Pantaleo, M. Urbini, V. Indio, G. Ravegnini, M. Nannini, M. De Luca, G. Tarantino, S. Angelini, A. Gronchi, B. Vincenzi, G. Grignani, C. Colombo, **E. Fumagalli**, L. Gatto, M. Saponara, M. Ianni, P. Paterini, D. Santini, MG Pirini, C. Ceccarelli, A. Altimari, E. Gruppioni, S. Renne, P. Collini, S. Stacchiotti, G. Brandi, P. G. Casali, AD Pinna, A. Astolfi, G. Biasco Genome-wide Analyses Identifies MEN1 and MAX Mutations and a Neuroendocrine-like Molecular Heterogeneity in Quadruple WT GIST. *Mol Cancer Res*. 2017 Jan 27. pii: molcanres.0376.2016. doi: 10.1158/1541-7786.MCR-16-0376. [Epub ahead of print]
- Nannini M, Nigro MC, Vincenzi B, **Fumagalli E**, Grignani G, D'Ambrosio L, Badalamenti G, Incorvaia L, Bracci R, Gasperoni S, Saponara M, Gatto L, Indio V, Astolfi A, Di Scioscio V, Casali PG, Tonini G, Aglietta M, Russo A, Biasco G, Pantaleo MA. Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. *Ther Adv Med Oncol*. 2017 Dec;9(12):731-739. doi: 10.1177/1758834017742627. Epub 2017 Dec 19.
- Colia V, **Fumagalli E**, Provenzano S, Bertulli R, Stacchiotti S, Morosi C, Collini P, Gronchi A, Casali PG, Sanfilippo R. High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma. *Sarcoma*. 2017;2017:3739159. doi: 10.1155/2017/3739159. Epub 2017 Aug 30.
- Colia V, Fiore M, Provenzano S, Fumagalli E, Bertulli R, Morosi C, Dei Tos AP, Barisella M, Gronchi A, Casali PG, Sanfilippo R. Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma. *Clin Sarcoma Res*. 2017 Aug 22;7:16. doi: 10.1186/s13569-017-0082-6. eCollection 2017.
- Joensuu H, Blay JY, Comandone A, Martin-Broto J, **Fumagalli E**, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer S, Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A. Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. *Br J Cancer*. 2017 Oct 24;117(9):1278-1285. doi: 10.1038/bjc.2017.290. Epub 2017 Aug 29.
- Casali PG, Zalcborg J, Le Cesne A, Reichardt P, Blay JY, Lindner LH, Judson IR, Schöffski P, Leyvraz S, Italiano A, Grünwald V, Pousa AL, Kotasek D, Sleijfer S, Kerst JM, Rutkowski P, **Fumagalli E**, Hogendoorn P, Litière S, Marreaud S, van der Graaf W, Gronchi A, Verweij J; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group. Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. *J Clin Oncol*. 2017 May 20;35(15):1713-1720. doi: 10.1200/JCO.2016.71.0228. Epub 2017 Mar 31.
- Vincenzi B, Nannini M, Grignani G, **Fumagalli E**, Gasperoni S, D'Ambrosio L, Badalamenti G, Dei Tos AP, Incorvaia L, Casali P, Santini D, Tonini G, Stellato M, Catania G, Spalato Ceruso M, Pantaleo MA. Rechallenge in GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey. *Ann Oncol*. 2017 Oct;28 Suppl 6
- Vincenzi B, Nannini M, Badalamenti G, Grignani G, **Fumagalli E**, Gasperoni S, D'Ambrosio L, Incorvaia L, Stellato M, Spalato Ceruso M, Napolitano A, Valeri S, Santini D, Tonini G, Casali PG, Dei Tos AP, Pantaleo MA. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. *Ther Adv Med Oncol*. 2018 Aug 29;10:1758835918794623. doi: 10.1177/1758835918794623. eCollection 2018.
- Reichardt P, Schlemmer M, Delgado Perez JR, Papai Z, Prausova J, Melichar B, **Fumagalli E**, Barone C, Bauer S, Pustowka A, Crippa S, Castellana R, Quiering C, Le Cesne A. Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting. *Oncol Res Treat*. 2019;42(12):629-635. doi: 10.1159/000502749. Epub 2019 Sep 24

- Pantaleo MA, Tarantino G, Agostinelli C, Urbini M, Nannini M, Saponara M, Castelli C, Stacchiotti S, **Fumagalli E**, Gatto L, Santini D, De Leo A, Marafioti T, Akarca A, Sabattini E, Pession A, Ardizzoni A, Indio V, Astolfi A. Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response. *Oncoimmunology*. 2019 Jun 4;8(9):e1617588. doi: 10.1080/2162402X.2019.1617588. eCollection 2019
- Tirota F, **Fumagalli E**, Colombo C, Morosi C, Barisella M, Radaelli S, Frezza AM, Casali PG, Gronchi A, Fiore M. Management of complicated tumor response to tyrosine-kinase inhibitors in gastrointestinal stromal tumors. *J Surg Oncol*. 2019 Aug;120(2):256-261. doi: 10.1002/jso.25491. Epub 2019 May 7
- Fucà G, Hindi N, Ray-Coquard I, Colia V, Dei Tos AP, Martin-Broto J, Brahmi M, Collini P, Lorusso D, Raspagliesi F, Pantaleo MA, Vincenzi B, **Fumagalli E**, Gronchi A, Casali PG, Sanfilippo R. Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. *Oncologist*. 2019 Jul;24(7):e536-e541. doi: 10.1634/theoncologist.2018-0338. Epub 2018 Dec 5
- Sanfilippo R, Jones RL, Blay JY, Le Cesne A, Provenzano S, Antoniou G, Mir O, Fucà G, **Fumagalli E**, Bertulli R, Stacchiotti S, Brahmi M, Grosso F, Dufresne A, Hindi N, Sbaraglia M, Gronchi A, Collini P, Dei Tos AP, Casali PG. Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). *Clin Cancer Res*. 2019 Sep 1;25(17):5295-5300. doi: 10.1158/1078-0432.CCR-19-0288. Epub 2019 Jun 19.
- Urbini M, Indio V, Tarantino G, Ravegnini G, Angelini S, Nannini M, Saponara M, Santini D, Ceccarelli C, Fiorentino M, Vincenzi B, **Fumagalli E**, Casali PG, Grignani G, Pession A, Ardizzoni A, Astolfi A, Pantaleo MA. Gain of FGF4 is a frequent event in KIT/PDGFR/SDH/RAS-P WT GIST. *Genes Chromosomes Cancer*. 2019 Sep;58(9):636-642. doi: 10.1002/gcc.22753. Epub 2019 Apr 16
- IJzerman NS, Mohammadi M, Tzanis D, Gelderblom H, Fiore M, **Fumagalli E**, Rutkowski P, Bylina E, Zavrakidis I, Steeghs N, Bonenkamp HJ, van Etten B, Grünhagen DJ, Rasheed S, Tekkis P, Honoré C, van Houdt W, van der Hage J, Bonvalot S, Schrage Y, Smith M. Quality of treatment and surgical approach for rectal gastrointestinal stromal tumour (GIST) in a large European cohort. *Eur J Surg Oncol*. 2020 Jun;46(6):1124-1130. doi: 10.1016/j.ejso.2020.02.033. Epub 2020 Mar 6. *Eur J Surg Oncol*. 2020.
- Sanfilippo R, Fabbroni C, Fucà G, **Fumagalli E**, Morosi C, Sbaraglia M, Gronchi A, Collini P, Dei Tos AP, Casali PG. Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors. *Clin Cancer Res*. 2020 Oct 15;26(20):5534-5538. doi: 10.1158/1078-0432.CCR-20-1191. Epub 2020 Jun 30. *Clin Cancer Res*. 2020. PMID: 32605908
- Gronchi A, Bonvalot S, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, **Fumagalli E**, Judson IR, Italiano A, Gelderblom HJ, van Coevorden F, Penel N, Kopp HG, Duffaud F, Goldstein D, Broto JM, Wardelmann E, Marréaud S, Smithers M, Le Cesne A, Zaffaroni F, Litière S, Blay JY, Casali PG. Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. *JAMA Surg*. 2020 Jun 1;155(6):e200397. doi: 10.1001/jamasurg.2020.0397. Epub 2020 Jun 17
- Fucà G, Fabbroni C, Mancari R, Manglaviti S, Bogani G, **Fumagalli E**, Bertulli R, Morosi C, Collini P, Raspagliesi F, Colombo N, Casali PG, Sanfilippo R. Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers. *Clin Sarcoma Res*. 2020 Aug 28;10:17.
- Vincenzi B, Napolitano A, Fiocco M, Mir O, Rutkowski P, Blay JY, Reichardt P, Joensuu H, **Fumagalli E**, Gennatas S, Hindi N, Nannini M, Spalato Ceruso M, Italiano A, Grignani G, Brunello A, Gasperoni S, De Pas T, Badalamenti G, Pantaleo MA, van Houdt WJ, IJzerman NS, Steeghs N, Gelderblom H, Desar IME, Falkenhorst J, Silletta M, Sbaraglia M, Tonini G, Martin-Broto J, Hohenberger P, Le Cesne A, Jones RL, Dei Tos AP, Gronchi A, Bauer S, Casali PG. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. *Clin Cancer Res*. 2021 Oct 6.
- Fabbroni C, Fucà G, Ligorio F, **Fumagalli E**, Barisella M, Collini P, Morosi C, Gronchi A, Dei Tos AP, Casali PG, Sanfilippo R. Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin. *Cancers (Basel)*. 2021 Mar 22;13(6):1453.
- Nannini M, Rizzo A, Nigro MC, Vincenzi B, Mazzocca A, Grignani G, Merlini A, D'Ambrosio L, Tolomeo F, Badalamenti G, Incorvaia L, Bonasera A, **Fumagalli E**, Miliziano D, Ligorio F, Brunello A, Chiusole B, Gasperoni S, Novelli M, Pantaleo MA. Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study. *ESMO Open*. 2021 Aug;6(4):100222.
- Casali PG, Le Cesne A, Velasco AP, Kotasek D, Rutkowski P, Hohenberger P, **Fumagalli E**, Judson IR, Italiano A, Gelderblom H, Penel N, Hartmann JT, Duffaud F, Goldstein D, Martin-Broto J, Gronchi A, Wardelmann E, Marréaud S, Zalcberg JR, Litière S, Blay JY, Casali PG, et al. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft

Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS). *Ann Oncol.* 2021 Apr;32(4):533-541.

- Fabbri C, Fucà G, Ligorio F, **Fumagalli E**, Barisella M, Collini P, Morosi C, Gronchi A, Dei Tos AP, Casali PG, Sanfilippo R. Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin. *Cancers (Basel).* 2021 Mar 22;13(6):1453
- Pantaleo MA, Urbini M, Schipani A, Nannini M, Indio V, De Leo A, Vincenzi B, Brunello A, Grignani G, Casagrande M, **Fumagalli E**, Conca E, Saponara M, Gruppioni E, Altimari A, De Biase D, Tallini G, Ravegnini G, Turchetti D, Seri M, Ardizzoni A, Secchiero P, Astolfi A. SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor. *Front Oncol.* 2022 Jan 4;11:778461.
- Vincenzi B, Napolitano A, Fiocco M, Mir O, Rutkowski P, Blay JY, Reichardt P, Joensuu H, **Fumagalli E**, Gennatas S, Hindi N, Nannini M, Spalato Ceruso M, Italiano A, Grignani G, Brunello A, Gasperoni S, De Pas T, Badalamenti G, Pantaleo MA, van Houdt WJ, IJzerman NS, Steeghs N, Gelderblom H, Desar IME, Falkenhorst J, Silletta M, Sbaraglia M, Tonini G, Martin-Broto J, Hohenberger P, Le Cesne A, Jones RL, Dei Tos AP, Gronchi A, Bauer S, Casali PG. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. *Clin Cancer Res.* 2022 Apr 14;28(8):1672-1679.
- van de Wal D, Elie M, Le Cesne A, **Fumagalli E**, den Hollander D, Jones RL, Marquina G, Steeghs N, van der Graaf WTA, Husson O. Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature. *Cancers (Basel).* 2022 Apr 5;14(7):1832.

I authorize the processing of personal data according to the Legislative Decree 196/03 and EU Regulation 679/2016